SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced the broad availability of mRNA-Seq, a new product for full-length, complementary DNA (cDNA) sequencing on the Genome Analyzer. In contrast to tiling and exon arrays, researchers can use mRNA-Seq to obtain a more in-depth, comprehensive view of the transcriptome, revealing aspects previously unseen using array-based or expression sequence tag (EST) technologies.
